Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951

[1]  R. Mirimanoff,et al.  Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. , 2009, Neuro-oncology.

[2]  K. Hoang-Xuan,et al.  Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas. , 2008, Neuro-oncology.

[3]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[4]  K. Aldape,et al.  Anaplastic Oligodendroglial Tumors: Refining the Correlation among Histopathology, 1p 19q Deletion and Clinical Outcome in Intergroup Radiation Therapy Oncology Group Trial 9402 , 2008, Brain pathology.

[5]  G. Reifenberger,et al.  BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. , 2008, The Journal of clinical investigation.

[6]  V. P. Collins,et al.  1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas , 2008, Oncogene.

[7]  Joseph K. Pickrell,et al.  A mixture model approach to multiple testing for the genetic analysis of gene expression , 2007, BMC proceedings.

[8]  Emmanuel Barillot,et al.  BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas , 2007, International journal of cancer.

[9]  B. Scheithauer,et al.  The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.

[10]  R. Fimmers,et al.  Identification of genomic aberrations associated with shorter overall survival in patients with oligodendroglial tumors , 2007, International journal of cancer.

[11]  Caterina Giannini,et al.  Panel Review of Anaplastic Oligodendroglioma From European Organization for Research and Treatment of Cancer Trial 26951: Assessment of Consensus in Diagnosis, Influence of 1p/19q Loss, and Correlations With Outcome , 2007, Journal of neuropathology and experimental neurology.

[12]  L. Chin,et al.  Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. , 2006, Cancer research.

[13]  C. Miller,et al.  Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Shaw,et al.  A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. , 2006, Cancer research.

[15]  Yuri Kotliarov,et al.  High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. , 2006, Cancer research.

[16]  P. Burger,et al.  Identification of der(1;19)(q10;p10) in Five Oligodendrogliomas Suggests Mechanism of Concurrent 1p and 19q Loss , 2006, Journal of neuropathology and experimental neurology.

[17]  M. J. van den Bent,et al.  1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. , 2006, European journal of cancer.

[18]  D. Pearson,et al.  Application of array CGH on archival formalin-fixed paraffin-embedded tissues including small numbers of microdissected cells , 2006, Laboratory Investigation.

[19]  P. Wesseling,et al.  Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. , 2006, The Journal of molecular diagnostics : JMD.

[20]  Emmanuel Barillot,et al.  CAPweb: a bioinformatics CGH array Analysis Platform , 2006, Nucleic Acids Res..

[21]  Denis Lacombe,et al.  Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Walter Curran,et al.  Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Rebecca A Betensky,et al.  Glioma test array for use with formalin-fixed, paraffin-embedded tissue: array comparative genomic hybridization correlates with loss of heterozygosity and fluorescence in situ hybridization. , 2006, The Journal of molecular diagnostics : JMD.

[24]  C. Nutt.  Molecular genetics of oligodendrogliomas: a model for improved clinical management in the field of neurooncology. , 2005, Neurosurgical focus.

[25]  G. Reifenberger,et al.  Molecular classification of human gliomas using matrix‐based comparative genomic hybridization , 2005, International journal of cancer.

[26]  Michael R Rossi,et al.  Identification of consistent novel submegabase deletions in low‐grade oligodendrogliomas using array‐based comparative genomic hybridization , 2005, Genes, chromosomes & cancer.

[27]  Olivier Delattre,et al.  Two types of chromosome 1p losses with opposite significance in gliomas , 2005, Annals of neurology.

[28]  L. Recht,et al.  High-resolution genome-wide mapping of genetic alterations in human glial brain tumors. , 2005, Cancer research.

[29]  Ivan Smirnov,et al.  Array Comparative Genomic Hybridization Identifies Genetic Subgroups in Grade 4 Human Astrocytoma , 2005, Clinical Cancer Research.

[30]  K. Aldape,et al.  Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. , 2005, Cancer research.

[31]  B. Feuerstein,et al.  Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas , 2005, Genes, chromosomes & cancer.

[32]  K. Aldape,et al.  Small cell astrocytoma: An aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma , 2004, Cancer.

[33]  T. Shiraishi,et al.  Detrended fluctuation analysis of genome-wide copy number profiles of glioblastomas using array-based comparative genomic hybridization. , 2004, Neuro-oncology.

[34]  Catherine L Nutt,et al.  The Oligodendroglial Lineage Marker OLIG2 Is Universally Expressed in Diffuse Gliomas , 2004, Journal of neuropathology and experimental neurology.

[35]  K. Roth,et al.  Prognostic Value of 1p, 19q, 9p, 10q, and EGFR‐FISH Analyses in Recurrent Oligodendrogliomas , 2004, Journal of neuropathology and experimental neurology.

[36]  G. Barnett,et al.  Characterization of the 1p/19q Chromosomal Loss in Oligodendrogliomas Using Comparative Genomic Hybridization Arrays (CGHa) , 2004, Journal of neuropathology and experimental neurology.

[37]  B. Scheithauer,et al.  Clinical Utility of Fluorescence In Situ Hybridization (FISH) in Morphologically Ambiguous Gliomas with Hybrid Oligodendroglial/Astrocytic Features , 2003, Journal of neuropathology and experimental neurology.

[38]  G. Reifenberger,et al.  The WHO Classification of Tumors of the Nervous System , 2002, Journal of neuropathology and experimental neurology.

[39]  R A Betensky,et al.  Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. , 2001, Cancer research.

[40]  D. Louis,et al.  Glioma classification: a molecular reappraisal. , 2001, The American journal of pathology.

[41]  Jean-Yves Delattre,et al.  OLIG2 as a specific marker of oligodendroglial tumour cells , 2001, The Lancet.

[42]  Ho-Keung Ng,et al.  Detection of Multiple Gene Amplifications in Glioblastoma Multiforme Using Array-Based Comparative Genomic Hybridization , 2001, Laboratory Investigation.

[43]  R A Betensky,et al.  Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  B. Scheithauer,et al.  Oligodendrogliomas: Reproducibility and Prognostic Value of Histologic Diagnosis and Grading , 2001, Journal of neuropathology and experimental neurology.

[45]  B. Scheithauer,et al.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[47]  G. Reifenberger,et al.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. , 1994, The American journal of pathology.

[48]  M. Alonso,et al.  Gene dosage and mutational analyses of EGFR in oligodendrogliomas. , 2007, International journal of oncology.

[49]  Takaaki Kirino,et al.  Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.